CN1303947C - Medicine eluted cardiovascular frame and its preparing process - Google Patents
Medicine eluted cardiovascular frame and its preparing process Download PDFInfo
- Publication number
- CN1303947C CN1303947C CNB011426411A CN01142641A CN1303947C CN 1303947 C CN1303947 C CN 1303947C CN B011426411 A CNB011426411 A CN B011426411A CN 01142641 A CN01142641 A CN 01142641A CN 1303947 C CN1303947 C CN 1303947C
- Authority
- CN
- China
- Prior art keywords
- medicine
- biodegradable
- bracket
- support
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The present invention discloses a medicine eluted cardiovascular bracket and a preparation method thereof. The bracket is composed of a balloon dilatation bracket and a biodegradable layer which is coated on the bracket and covered with a medicine. The biodegradable materials comprise glycolide, one of the homopolymers or the copolymers of L-lactide or epsilon-caprolactone, and the copolymer of polyfunctional group amino acid and L-lactide or epsilon-caprolactone. The material of the biodegradable layer for covering the medicine is biodegradable macromolecular grafting heparin, and the medicine has the function of preventing restenosis. The bracket is prepared by the steps that a balloon dilatation bracket is prepared, and then dipped in a mixing system which is composed of the medicine with the function of preventing restenosis, the material of the biodegradable layer for covering the medicine, and a solvent; the bracket is taken out and dried to form the medicine eluted cardiovascular bracket of the present invention. The medicine eluted cardiovascular bracket of the present invention can prevent the occurrence of acute thrombus and subacute thrombus and simultaneously can promote the healing of damaged vessel walls and prevent the occurrence of advanced thrombus.
Description
Technical field
The present invention relates to a kind of medicinal support, particularly a kind ofly be used for cardiovascular balloon expandable stent that can discharge medicine.
Background technology
Dotter in 1964 and Judkings (Dotter CT, Jukines MP.Tranaluminal treatmant ofarteriosclerotic obstruction, 1964,30:654) notion of percutaneous transluminal angio plasty has been proposed, and hypothesis uses silicone rubber or plastics to come support blood vessels, unobstructed with blood flow in the maintenance lumen of vessels, 1987, Sigwart (Sigwart U, etal.Intravascular stents to prevent occlusion and restenosis after tranaluminal angioplasty.N Engl JMed, 1987; 316:701) grade is used for metal rack in the blood vessel coronary artery first, for treatment blood vessel blockage disease provides good approach.
Ideal support should possess following feature: (1) better biocompatibility: minimum blood coagulation enhancing effect, and implant the back and be difficult for blood coagulation reaction and thrombosis take place, be difficult for causing the inflammatory reaction and the neointimal hyperplasia of blood vessel wall; (2) easy polarization; (3) have pliability preferably, easily shift diseased region onto; (4) easily expansion, support force is strong and mechanical robustness arranged.
Coronary atherosclerotic heart disease is one of major reason of cardiovascular disease death, although emergency treatment reconstructing blood vessel technology [comprises thromboembolism treatment, coronary artery bypass grafting CCABG], percutaneous transluminal coronary angioplasty (PTCA)] saved a large amount of dying patients, but the vascular restenosis incidence rate behind CABG and the PTCA still very high (restenosis rate is 40% behind the PTCA), it mainly comes from inner membrance, middle film hypertrophy and the comprehensive function of blood vessel wall construction geometry reconstruct institute, the appearance of coronary artery bracket and application have obviously reduced the vascular restenosis incidence rate behind the PTCA, yet the clinical practice of support is limited by following Several Factors: 1) subacute stent thrombosis forms (3-10 days); 2) in-stent restenosis in late period (about half a year) (incidence rate about about 20%); 3) tardy property thrombosis.
Patent EP132060 discloses a kind of balloon expandable formula stainless steel stent, and at present, this balloon expandable stainless steel stent can satisfy above-mentioned back three's condition, but subacute stent thrombosis and in-stent restenosis at a specified future date are two big complication of balloon expandable stainless steel stent.For solving an above-mentioned difficult problem, people constantly design and release the biological characteristics that New-support improves support, and drug-eluting stent is exactly wherein a kind of.
Human body drug resistance dosage is too low, is difficult to reach valid density at target site, and this may be the reason that systemic administration does not prove effective.And active drug is transported to the arterial injury place by support, will help the treatment of complication.
United States Patent (USP) U.S.6,231,600 for preventing the in-stent restenosis after support is implanted and the generation of thrombosis, designed a kind of overbrushing layer support technology: ground floor is made up of polymer, anti-restenosis (paclitaxel) and cross-linking agent (aziridine), the second layer is anticoagulant medicine heparin, two-layer between by the cross-linking agent bonding.But the technology of preparing of this Patent publish is comparatively complicated, and has introduced harmful substance (aziridine), is unfavorable for promoting the use of.
Summary of the invention
The technical issues that need to address of the present invention are to disclose a kind of medicine eluted cardiovascular frame and preparation method thereof, on this support, applied the Biodegradable high-molecular grafting heparin that one deck has anti-restenosis function, after support is implanted soon, anti-restenosis medicaments discharges in a large number, fully suppress neointimal hyperplasia, the continual and steady release of heparin, can prevent acute, the generation of subacute stent thrombosis, can promote simultaneously the healing of injured blood vessel wall, prevent the generation of advanced thrombus, comparatively complicated to overcome subacute stent thrombosis that prior art exists and restenosis at a specified future date and technology of preparing, and introduced harmful substance (aziridine), be unfavorable for the defective promoted the use of, satisfy people's demand.
Technical scheme of the present invention;
Medicine eluted cardiovascular frame of the present invention is made of balloon expandable stent and the biodegradable layers that is coated in the coating medicine on the support.
Said balloon expandable stent can be made by rustless steel or biodegradable material.Biodegradable material comprise Acetic acid, hydroxy-, bimol. cyclic ester (glycolic acid, GA), the L-lactide (L-lactic acid, LLA) or 6-caprolactone (caprolactone, a kind of in homopolymer CL) or the copolymer and with the copolymer of multifunctional amino acid.This preparation methods is a prior art, and its preparation method can be consulted document (Makromol.Chem.1987,188:1809-1814) disclosed method.Concrete preparation method can be referring to embodiment 1.
The biodegradable layer material of coating medicine is a kind of Biodegradable high-molecular grafting heparin, and its preparation method is a prior art, can consult the disclosed method of patent (application number 01132179.2).Concrete preparation method can referring to
Embodiment 2.
Said medicine is a kind of medicine with anti-restenosis function, comprises in rapamycin, dactinomycin, ciclosporin A or the paclitaxel one or more.
Above-mentioned medicine eluted cardiovascular frame is preparation like this:
(1) at first prepares the balloon expandable stainless steel stent, or prepare the Biodegradable material support according to the technology of United States Patent (USP) U.S.5670161 patent disclosure according to the disclosed technology of patent EP132060;
(2) support be impregnated in the mixed system of the biodegradable layer material of medicine with anti-restenosis function, coating medicine and solvent composition, generally speaking, dip time is 10～60s; Said solvent be for dissolving the biodegradable layer material of coating medicine, comprises a kind of and composition thereof in chloroform, acetone or the DMC dimethyl carbonate;
(3) take out support, after the drying, promptly obtain medicine eluted cardiovascular frame of the present invention.
According to the present invention, support is etching in advance, resurfacing, etching again after also can coating.
Term " etching " refers to the laser clean cut.
By above-mentioned disclosed technical scheme as seen, the present invention in stent surface coated one Biodegradable high-molecular grafting heparin with anti-restenosis function, the continual and steady release of heparin, can prevent generation acute, subacute stent thrombosis, can promote simultaneously the healing of injured blood vessel wall, prevent the generation of advanced thrombus.Compare with traditional heparin support, the not anti-body fluid that has overcome physical blending washes away (heparin is a water soluble drug), and the defective of introducing noxious substance in the chemical bond process.
Description of drawings
Fig. 1 is the structural representation of balloon expandable stent.
Fig. 2 is the structural representation after the balloon expandable stent expansion.
The specific embodiment
Embodiment 1
The preparation of Biodegradable material:
Take by weighing 70 parts of L-LA, 5 parts of GA and 25 parts of ε-CL in exsiccant, as to have stirrer polymerization bottle, use N
2Replace 3 times, place 160 ℃ of oil baths, after waiting to melt, add the 0.02g/ml stannous octoate chloroformic solution (catalytic amount is the 0.02wt% of monomer mass) of certain volume, chloroform is removed in decompression, stirs reaction 5h down, and polymer dissolves with chloroform, ethanol precipitation.(gel permeationchromatography GPC) characterizes the molecular weight of resulting polymers, and molecular weight is greater than 100,000 with gel permeation chromatography.
Embodiment 2
The preparation of heparinization poly-(lactic-co-glycolic acid-aminoacid):
Take by weighing morpholine diketone derivatives monomer that 0.1molL-lactide and 0.05mol contain benzyloxy protection glutamic acid in exsiccant, as to have stirrer polymerization bottle, use N
2Replace 3 times, place 160 ℃ of oil baths, after waiting to melt, add the 0.02g/ml stannous octoate chloroformic solution of certain volume, chloroform is removed in decompression, stirs reaction 5h down, and polymer dissolves with chloroform, ethanol precipitation.Resulting polymers is with the Pd/C catalyst, and hydrogen bubbling 40 is sloughed benzyloxy, is promptly gathered (lactic-co-glycolic acid-glutamic acid).
Contain amino, carboxyl in the heparin, to gather in the mixed solvent that (lactic-co-glycolic acid-aspartic acid) be dissolved in oxolane and water, other takes by weighing a certain amount of (according to the Gel Permeation Chromatography of polymer, be called for short GPC molecular weight and amino acid content) heparin sodium be dissolved in the low amounts of water, regulating pH with diluted acid is about 4.Both are mixed, Dcci (the dicyclohexylcarbodiimide that adds equivalent, DCC), stir 24h down at 4 ℃, removal of solvent under reduced pressure adds an amount of chloroform again, the elimination insoluble matter, gained solution petroleum ether precipitation, dry 24h under the room temperature promptly obtains heparinization macromolecule (heparinized polymer).
Embodiment 3
0.1 gram heparinization poly-(lactic-co-glycolic acid-aminoacid) and the 0.1 anti-restenosis medicaments rapamycin of gram (Rampamycin) are dissolved in the 5ml chloroform, again will balloon expandable stent as shown in Figure 1 be dipped in this solution about 30s, dry up standby after the taking-up.This support can overcome in-stent restenosis, and can prevent formation acute, subacute stent thrombosis, and heparin has anti-inflammatory effect simultaneously, can suppress the foreign body inflammatory reaction of support, promotes the healing of blood vessel wound.
Embodiment 4
0.1 gram heparinization poly-(lactic-co-glycolic acid-aminoacid) and the 0.2 anti-restenosis medicaments dactinomycin of gram (Actonimycin) are dissolved in the 5ml chloroform, again will balloon expandable stent as shown in Figure 1 be dipped in this solution about 30s, dry up standby after the taking-up.This support can overcome in-stent restenosis, and can prevent formation acute, subacute stent thrombosis, and heparin has anti-inflammatory effect simultaneously, can suppress the foreign body inflammatory reaction of support, promotes the healing of blood vessel wound.
Embodiment 5
0.1 gram heparinization poly-(lactic-co-glycolic acid-aminoacid) and the 0.4 anti-restenosis medicaments paclitaxel of gram (Taxol) are dissolved in the 5ml chloroform, again will balloon expandable stent as shown in Figure 1 be dipped in this solution about 30s, dry up standby after the taking-up.This support can overcome in-stent restenosis, and can prevent formation acute, subacute stent thrombosis, and heparin has anti-inflammatory effect simultaneously, can suppress the foreign body inflammatory reaction of support, promotes the healing of blood vessel wound.
Embodiment 6
Get a medical stainless steel tubing, coat heparinization poly-(lactic-co-glycolic acid-aminoacid) at internal layer, outer is that coating material coats paclitaxel with heparinization poly-(lactic-co-glycolic acid-aminoacid), again pipe is become balloon expandable stent with laser ablation.This rack inner wall contacts with blood, owing to there is heparin coating to have the anticoagulation function, can prevent the formation of tampon; Skin slowly releases paclitaxel, and paclitaxel can suppress neointimal hyperplasia, thereby alleviates in-stent restenosis, and heparinization poly-(lactic-co-glycolic acid-aminoacid) can promote the healing of blood vessel wound simultaneously.
Embodiment 7
Get a medical tubing, coat heparinization poly-(lactic-co-glycolic acid-aminoacid) at internal layer, outer is that coating material coats dactinomycin with heparinization poly-(lactic-co-glycolic acid-aminoacid), again pipe is become balloon expandable stent with laser ablation.This rack inner wall contacts with blood, owing to there is heparin coating to have the anticoagulation function, can prevent the formation of tampon; Skin slowly releases dactinomycin, and dactinomycin can suppress neointimal hyperplasia, thereby alleviates in-stent restenosis, and heparinization poly-(lactic-co-glycolic acid-aminoacid) can promote the healing of blood vessel wound simultaneously.
Embodiment 8
Get a medical tubing, coat heparinization poly-(lactic-co-glycolic acid-aminoacid) at internal layer, outer is that coating material coats rapamycin with heparinization poly-(lactic-co-glycolic acid-aminoacid), again pipe is become balloon expandable stent with laser ablation.This rack inner wall contacts with blood, owing to there is heparin coating to have the anticoagulation function, can prevent the formation of tampon; Skin slowly releases rapamycin, and rapamycin can suppress neointimal hyperplasia, thereby alleviates in-stent restenosis, and heparinization poly-(lactic-co-glycolic acid-aminoacid) can promote the healing of blood vessel wound simultaneously.
Claims (7)
1. a medicine eluted cardiovascular frame is made of balloon expandable stent and the biodegradable layers that is coated in the coating medicine on the support, and said balloon expandable stent is made by rustless steel or biodegradable material;
It is characterized in that, said Biodegradable material comprise a kind of in the homopolymer of Acetic acid, hydroxy-, bimol. cyclic ester, L-lactide or 6-caprolactone or the copolymer and with the copolymer of multifunctional amino acid;
The biodegradable layer material of said coating medicine is a Biodegradable high-molecular grafting heparin;
Said medicine is a kind of medicine with anti-restenosis function.
2. angiocarpy bracket as claimed in claim 1 is characterized in that, the medicine with anti-restenosis function comprises one or more in rapamycin, dactinomycin, ciclosporin A or the paclitaxel.
3. the preparation method of angiocarpy bracket as claimed in claim 1 or 2 is characterized in that comprising the steps:
(1) at first prepares balloon expandable stainless steel stent or Biodegradable material support;
(2) support be impregnated in the mixed system of the biodegradable layer material of medicine with anti-restenosis function, coating medicine and solvent composition;
(3) take out support, after the drying, promptly obtain medicine eluted cardiovascular frame of the present invention.
4. preparation method as claimed in claim 3 is characterized in that, said solvent comprises a kind of and composition thereof in chloroform, acetone or the DMC dimethyl carbonate.
5. preparation method as claimed in claim 3 is characterized in that, dip time is 10～60s.
6. preparation method as claimed in claim 3 is characterized in that support is etching in advance, resurfacing or coat after etching again.
7. as claim 4 or 5 described preparation methoies, it is characterized in that support is etching in advance, resurfacing or coat after etching again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011426411A CN1303947C (en) | 2001-12-13 | 2001-12-13 | Medicine eluted cardiovascular frame and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011426411A CN1303947C (en) | 2001-12-13 | 2001-12-13 | Medicine eluted cardiovascular frame and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1355005A CN1355005A (en) | 2002-06-26 |
| CN1303947C true CN1303947C (en) | 2007-03-14 |
Family
ID=4676873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011426411A Expired - Fee Related CN1303947C (en) | 2001-12-13 | 2001-12-13 | Medicine eluted cardiovascular frame and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1303947C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110711056A (en) * | 2014-10-28 | 2020-01-21 | 株式会社Jimro | Drug eluting stent |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101467921B (en) * | 2001-11-05 | 2012-08-15 | 生物传感器国际集团有限公司 | Method for producing bracket for eluting medicament |
| CN1306917C (en) * | 2002-12-17 | 2007-03-28 | 微创医疗器械(上海)有限公司 | Scaffold for preventing/treating intravascular re-stricture by compound action mechanism |
| EP1516597A4 (en) * | 2002-06-27 | 2010-11-10 | Microport Medical Shanghai Co | Drug eluting stent |
| CN100346850C (en) * | 2003-05-28 | 2007-11-07 | 微创医疗器械(上海)有限公司 | Medicine coating rack |
| AU2003299590B8 (en) * | 2002-12-09 | 2010-04-08 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
| CN100371032C (en) * | 2004-01-16 | 2008-02-27 | 东南大学 | Re-stricture preventing medicinal sustained releasing bracket and its preparation |
| US7875282B2 (en) * | 2004-03-22 | 2011-01-25 | Cordis Corporation | Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury |
| JP2007532185A (en) * | 2004-04-05 | 2007-11-15 | メディバス エルエルシー | Bioactive stent for type II diabetes and method of use thereof |
| CN100450557C (en) * | 2004-08-13 | 2009-01-14 | 重庆大学 | Medication eluting type blood vessel bracket |
| CN1799650B (en) * | 2005-12-30 | 2010-07-14 | 李文涛 | Method for preparing biodegradable drug-carried high molecular material stent |
| US20100049308A1 (en) * | 2006-11-20 | 2010-02-25 | Lepu Medical Technology (Beijing) Co., Ltd. | Vessel stent with multi drug-coatings |
| CN101199873B (en) * | 2006-12-14 | 2013-06-19 | 乐普（北京）医疗器械股份有限公司 | Medicament elution instrument nanometer class colon washer machineole drug releasing structure and preparing method thereof |
| CN101641059B (en) * | 2007-02-14 | 2011-10-19 | 山东瑞安泰医疗技术有限公司 | Intracoronary stent with asymmetric drug releasing controlled coating |
| CN101161300B (en) | 2007-11-27 | 2011-03-16 | 北京美中双和医疗器械有限公司 | Arsenic trioxide medicament elution bracket and its preparation method |
| JP5693456B2 (en) * | 2009-08-26 | 2015-04-01 | 大塚メディカルデバイス株式会社 | Intraluminal medical device and method for manufacturing the same |
| CN102784418B (en) * | 2012-08-10 | 2014-04-16 | 中国医学科学院生物医学工程研究所 | Procedurally-released biological drug nanoporous intravascular stent, preparation method and application thereof |
| CN102860890B (en) * | 2012-10-14 | 2014-12-17 | 梁春永 | Composite medicine carrying vessel stent and preparation method thereof |
| CN105797220B (en) * | 2014-12-31 | 2020-07-31 | 先健科技(深圳)有限公司 | Degradable iron-based alloy stent |
| CN106883451A (en) * | 2016-12-29 | 2017-06-23 | 高州市兆翔新材料有限公司 | A kind of nano kaoline |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591227A (en) * | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Drug eluting stent |
| WO1997010011A1 (en) * | 1995-09-11 | 1997-03-20 | Schneider (Usa) Inc. | Drug release stent coating process |
-
2001
- 2001-12-13 CN CNB011426411A patent/CN1303947C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591227A (en) * | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Drug eluting stent |
| WO1997010011A1 (en) * | 1995-09-11 | 1997-03-20 | Schneider (Usa) Inc. | Drug release stent coating process |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110711056A (en) * | 2014-10-28 | 2020-01-21 | 株式会社Jimro | Drug eluting stent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1355005A (en) | 2002-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1303947C (en) | Medicine eluted cardiovascular frame and its preparing process | |
| US8021678B2 (en) | Implantable medical device with polymer coating in a surface area to volume ratio providing surface erosion characteristics | |
| CN101264351B (en) | Composite coating cardiovascular medicaments elution stent and preparation thereof | |
| RU2363497C2 (en) | Pharmaceutical compositions | |
| US20090036352A1 (en) | Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof | |
| Gong et al. | Heparin-immobilized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents | |
| CN105833358B (en) | Intracranial drug eluting stent system and preparation method thereof | |
| JP5329435B2 (en) | Coronary stent with asymmetric drug release controlled coating | |
| CN101869723A (en) | Composite medicament stent for inhibiting cardiovascular restenosis and preparation method | |
| JP2000503555A (en) | Coating for biological material that can be introduced into the bloodstream or tissue of the human body | |
| JP2005530561A (en) | Silicone mixtures and composites for drug delivery | |
| CN101711710B (en) | Medicament eluting stent and preparation method thereof | |
| JP2004222953A (en) | Indwelling stent | |
| CN1557507A (en) | Re-stricture preventing medicinal sustained releasing bracket and its preparation | |
| CN101641059B (en) | Intracoronary stent with asymmetric drug releasing controlled coating | |
| CN1669597A (en) | Medicine eluted cardiovascular support | |
| CN1669595A (en) | Medicine eluted cardiovascular support | |
| CN1669596A (en) | Medicine eluted cardiovascular support | |
| CN201453424U (en) | Cardiovascular composite coating drug eluting stent | |
| RU2775427C1 (en) | Drug-eluting stent and method for production thereof | |
| JP2012506278A (en) | Coating II | |
| MXPA06007319A (en) | Parmaceutical compositions | |
| AU2007200756A1 (en) | Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof | |
| AU2009201507A1 (en) | Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |